GlassScriptPhysician profile
Salman Hasan
NPI 1316358492
$875.74
in general payments reported to CMS, 2019-2025
15 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $130 · 2020: $77.52 · 2021: $220 · 2022: $300 · 2023: $24.97 · 2024: $124.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $149.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $149.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Reflexion Medical, INC. | $166.42 | 2022 | |
| Inspire Medical Systems, INC. | $124.12 | 2024 | Inspire |
| Eisai INC. | $121.36 | 2021 | |
| Merck Sharp & Dohme LLC | $117.20 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $112.23 | 2020-2022 | |
| G1 Therapeutics, INC. | $86.89 | 2021 | |
| Janssen Biotech, INC. | $24.97 | 2023 | Erleada |
| Dendreon Pharmaceuticals LLC | $19.42 | 2022 | |
| Aveo Pharmaceuticals, INC. | $19.12 | 2022 | |
| Acceleron Pharma, INC. | $16.75 | 2020 | |
| Sanofi-Aventis U.S. LLC | $16.06 | 2020 | |
| Sun Pharmaceutical Industries INC. | $13.98 | 2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $13.24 | 2020 | |
| Alexion Pharmaceuticals, INC. | $12.56 | 2019 | |
| Taiho Oncology, INC. | $11.42 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Salman Hasan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.